```html

Zollinger‑Ellison‑type Hypercalcemia – A Complete Medical Guide

Overview

Zollinger‑Ellison‑type hypercalcemia refers to an elevated blood calcium level that occurs in patients with a Zollinger‑Ellison syndrome (ZES) as part of the multiple endocrine neoplasia type 1 (MEN 1) complex. In MEN 1, tumors develop in the parathyroid glands (causing primary hyperparathyroidism) alongside gastrin‑producing tumors (gastrinomas) of the pancreas or duodenum. The combination of excess gastrin and high calcium creates a distinct clinical picture that is sometimes described as “Zollinger‑Ellison‑type hypercalcemia.”

• Who it affects: Adults 30–60 years old, with a slight male preponderance in sporadic gastrinomas but an equal gender distribution in MEN 1.
• Prevalence: MEN 1 occurs in about 1–3 per 100,000 people worldwide; roughly 30–40 % of MEN 1 patients develop primary hyperparathyroidism, and 20–30 % develop a gastrinoma. Consequently, Zollinger‑Ellison‑type hypercalcemia is rare—estimated in <0.1 % of the general population but present in up to 6–10 % of patients with MEN 1.

Understanding this condition is crucial because untreated hypercalcemia can worsen the ulcer disease driven by gastrin excess and increase the risk of kidney stones, bone loss, and cardiovascular events.

Symptoms

Symptoms arise from two sources: (1) the hypercalcemia itself and (2) the acid‑hypersecretion caused by the gastrinoma. The overlap can make diagnosis challenging.

Symptoms of Hypercalcemia

• Kidney‑related: polyuria, polydipsia, nephrolithiasis (kidney stones), and occasional renal colic.
• Gastrointestinal: abdominal pain, constipation, nausea, vomiting, and loss of appetite.
• Neuro‑muscular: muscle weakness, fatigue, “brain fog,” confusion, depression, and in severe cases, seizures.
• Skeletal: bone pain, especially in the ribs, hips, or vertebrae; increased fracture risk.
• Cardiovascular: hypertension, shortened QT interval on ECG, and arrhythmias.

Symptoms of Zollinger‑Ellison Syndrome (Excess Gastrin)

• Recurrent or refractory peptic ulcers (often multiple and located distal to the duodenum).
• Profuse, watery diarrhea (often >3 L/day) that may be acid‑mediated.
• Abdominal cramping and bloating.
• Heartburn or gastro‑esophageal reflux disease (GERD) not responding to standard therapy.

Combined Presentation

Patients may notice that the ulcer symptoms worsen after a high‑calcium meal or when they develop kidney stones. The classic “Zollinger‑Ellison‑type hypercalcemia” triad includes:

1. Elevated serum calcium (>10.5 mg/dL).
2. Elevated fasting gastrin (>100 pg/mL) that does not suppress with secretin testing.
3. Acid‑related gastrointestinal symptoms (ulcers or diarrhea).

Causes and Risk Factors

Primary Causes

• MEN 1 (Multiple Endocrine Neoplasia Type 1): An inherited autosomal‑dominant mutation in the MEN1 tumor suppressor gene leads to hyperplasia of the parathyroid glands (producing excess PTH) and to gastrinomas.
• Primary Hyperparathyroidism (PHPT): Overactive parathyroid tissue releases too much parathyroid hormone (PTH), raising calcium levels.
• Gastrinoma: A neuroendocrine tumor that secretes gastrin, stimulating gastric acid and, indirectly, increasing bone resorption and calcium release.

Risk Factors

• Family history of MEN 1 or known MEN1 mutation.
• Previous diagnosis of PHPT or pancreatic neuroendocrine tumor.
• Exposure to high‑dose calcium or vitamin D supplements (rarely a trigger in the context of MEN 1).
• Age 30‑60 years (the typical window for MEN 1 tumor manifestation).

Diagnosis

Diagnosing Zollinger‑Ellison‑type hypercalcemia requires confirming both hypercalcemia and gastrin excess, then locating the tumors.

Step 1 – Laboratory Evaluation

• Serum Calcium: Total calcium >10.5 mg/dL or ionized calcium >1.30 mmol/L.
• Parathyroid Hormone (PTH): Elevated or inappropriately normal in the setting of high calcium confirms primary hyperparathyroidism.
• Fasting Serum Gastrin: Levels >100 pg/mL (or >10× upper limit) after an overnight fast.
• Secretin Stimulation Test: Gastrin rises >120 pg/mL after IV secretin in gastrinoma; helps differentiate from other causes of hypergastrinemia.
• Vitamin D, Phosphate, Creatinine: To assess renal function and rule out secondary causes.

Step 2 – Imaging for Tumor Localization

• Endoscopic Ultrasound (EUS): Sensitivity ~80 % for pancreaticoduodenal gastrinomas.
• Somatostatin Receptor Scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Detects neuroendocrine tumors with high accuracy (up to 95 %).
• CT/MRI Abdomen: Helps evaluate size, metastasis, and relationship to surrounding structures.
• Selective Venous Sampling: Rarely used; measures gastrin gradients to pinpoint occult tumors.

Step 3 – Genetic Testing

If MEN 1 is suspected, genetic counseling and testing for MEN1 mutations are recommended (American College of Medical Genetics guidelines).

Treatment Options

1. Manage Hypercalcemia

• Hydration: Intravenous normal saline (250–500 mL/hr) to promote calciuresis.
• Bisphosphonates (e.g., zoledronic acid): Inhibit bone resorption; effect within 2–4 days.
• Calcitonin: Rapid, short‑term reduction of calcium (used in severe cases).
• Denosumab: Monoclonal antibody for refractory hypercalcemia, especially in renal impairment.
• Parathyroidectomy: Definitive treatment for primary hyperparathyroidism; recommended when calcium >11.5 mg/dL, symptomatic disease, or >1 g bone loss.

2. Control Gastrin‑Driven Acid Hypersecretion

• Proton Pump Inhibitors (PPIs): High‑dose omeprazole 40–80 mg daily (or equivalent) is first line; they heal ulcers and reduce diarrhea.
• Histamine‑2 Receptor Antagonists (H2RAs): May be added for breakthrough symptoms.

3. Treat the Gastrinoma

• Surgical Resection: Enucleation or pancreaticoduodenectomy (Whipple) for localized tumors; offers the best chance for cure.
• Somatostatin Analogues (Octreotide, Lanreotide): Control gastrin secretion when surgery is not feasible or as adjuvant therapy.
• Targeted Therapy: Everolimus or sunitinib for metastatic neuroendocrine tumors (per NCCN guidelines).
• Peptide‑Receptor Radionuclide Therapy (PRRT): ^177Lu‑DOTATATE for somatostatin‑receptor positive disease.

4. Lifestyle Modifications

• Limit calcium‑rich foods (dairy, fortified products) if calcium remains mildly elevated after surgery.
• Avoid high‑acid foods (spicy, caffeinated, alcoholic) that exacerbate ulcer symptoms.
• Stay well‑hydrated (≥2 L water/day) to reduce stone formation.
• Quit smoking and maintain a healthy weight to reduce ulcer recurrence.

Living with Zollinger‑Ellison‑type Hypercalcemia

Daily Management Tips

• Medication Adherence: Take PPIs at the same time each day; monitor calcium‑lowering meds for side effects.
• Regular Lab Monitoring: Serum calcium, PTH, and gastrin every 3–6 months, or more often after any treatment change.
• Dietary Guidance:
  • Consume 1,200–1,500 mg calcium per day (unless told otherwise).
  • Prefer low‑oxalate vegetables (broccoli, kale) to lower stone risk.
  • Include vitamin D 800–1,000 IU daily if deficient, but avoid excess supplementation.
• Hydration: Aim for urine output >2 L/day; use a water bottle as a reminder.
• Physical Activity: Weight‑bearing exercise (30 min brisk walking, stair climbing) 3–5 times weekly to preserve bone density.
• Follow‑up Imaging: Annual abdominal MRI or CT if tumors were not removed; more frequent if residual disease.
• Support Networks: Join MEN 1 or neuroendocrine tumor patient groups for emotional support and up‑to‑date information.

Prevention

Because the condition is largely genetic, primary prevention focuses on early detection rather than avoidance.

• Family Screening: First‑degree relatives of patients with MEN 1 should undergo genetic testing and baseline calcium, PTH, and gastrin levels at age 8‑10 years (per NIH recommendations).
• Regular Surveillance: Annual biochemical testing and imaging for those with known MEN 1 mutations, even when asymptomatic.
• Healthy Lifestyle: While it won’t prevent the genetic mutation, maintaining a balanced diet, adequate hydration, and avoidance of smoking reduces the risk of complications such as kidney stones and bone loss.

Complications

If left untreated or inadequately managed, Zollinger‑Ellison‑type hypercalcemia can lead to serious health problems:

• Recurrent or perforated peptic ulcers → gastrointestinal bleeding, peritonitis.
• Nephrolithiasis and chronic kidney disease from calcium‑phosphate precipitation.
• Osteoporosis or osteopenia due to chronic bone resorption.
• Cardiovascular events – hypertension, arrhythmias, and coronary artery calcification.
• Neuropsychiatric effects – severe hypercalcemia can cause delirium, coma, or seizures.
• Metastatic gastrinoma – spreads to liver or lymph nodes, worsening prognosis.

When to Seek Emergency Care

References

• Mayo Clinic. Primary Hyperparathyroidism. Accessed May 2024.
• National Institutes of Health. Zollinger‑Ellison Syndrome. Genetics Home Reference. 2023.
• Cleveland Clinic. MEN 1 Overview. Updated 2024.
• American College of Gastroenterology. Guideline for Diagnosis and Management of ZES. 2022.
• World Health Organization. Neuroendocrine Tumors Fact Sheet. 2023.

```